Digital technology drives growth in biomanufacturing value chain

Photo: Frost & Sullivan / CNW.

SAN ANTONIO — The biomanufacturing sector is experiencing a digitalization transformation that is aligned with Industry 4.0. according to Frost & Sullivan’s recent analysis on the digital biomanufacturing industry. The report showed that digital tools applied across processes, monitoring, analytics, and operations have accelerated biomanufacturing with a data-driven approach.

“Digitalization improves the entire value chain of manufacturing biologics, competitive generic therapy (CGT) products, and vaccines,” said Neeraja Vettekudath, healthcare research analyst, Frost & Sullivan. “Automated processes, remote monitoring, and digital supply chains accelerate biomanufacturing rates of biopharmaceuticals.”

“Digitalization deploys advanced sensors, artificial intelligence (AI)/machine learning (ML), and blockchain to create platforms. It builds seamless biomanufacturing systems where information is passed from one stage to the next. This increases efficiency, creating growth opportunities for digital biomanufacturing solution providers, enablers, and adopters,” said Vettekudath.

To capitalize on the growth prospects of digital biomanufacturing, Frost & Sullivan suggests that market participants should:

• Invest in building digital twin models for predictive and data-driven biomanufacturing decisions.
• Make an initial investment in digital tools that streamline processes.
• Incorporate advanced software or AI tools to make sense of bioprocess data and accelerate the advancement toward developing robust and high-power processing systems that can use this data.

Developments in Digital Biomanufacturing: Technology Growth Opportunities is the latest addition to Frost & Sullivan’s Healthcare research and analyses.